



May 7, 2026

**BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation of Board Meeting**

**Ref.: Regulation 29 & 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Pursuant to Regulation 29 & 50 of the Listing Regulations, we wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday, May 19, 2026, inter-alia to consider and approve:

- i. the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31, 2026;
- ii. the proposal for realignment of security cover provided in respect of existing Non-Convertible Debentures (“NCDs”), post redemption of NCD of ₹ 1,250 Crores on April 16, 2026:

S. No.	Particulars	Details	
1	ISIN	INE634S07025	INE634S07033
2	Issue size (Amount in ₹)	12,50,00,00,000	25,00,00,00,000
3	Date of allotment	October 16, 2025	October 16, 2025
4	Date of Maturity	October 16,2026	November 16,2027

Further, in continuation of our earlier intimation dated March 27, 2026 under subject ‘Intimation of Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till May 21, 2026.

The above notice is also being uploaded on the website of the Company at [www.mankindpharma.com](http://www.mankindpharma.com).

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Kumar Jain**  
Company Secretary &  
Compliance Officer

**MANKIND PHARMA LIMITED**